The WACC of Livzon Pharmaceutical Group Inc (000513.SZ) is 8.9%.
Range | Selected | |
Cost of equity | 8.40% - 10.80% | 9.60% |
Tax rate | 15.40% - 16.80% | 16.10% |
Cost of debt | 5.00% - 5.00% | 5.00% |
WACC | 7.9% - 9.9% | 8.9% |
Category | Low | High |
Long-term bond rate | 2.7% | 3.2% |
Equity market risk premium | 6.1% | 7.1% |
Adjusted beta | 0.94 | 1 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 8.40% | 10.80% |
Tax rate | 15.40% | 16.80% |
Debt/Equity ratio | 0.16 | 0.16 |
Cost of debt | 5.00% | 5.00% |
After-tax WACC | 7.9% | 9.9% |
Selected WACC | 8.9% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for 000513.SZ:
cost_of_equity (9.60%) = risk_free_rate (2.95%) + equity_risk_premium (6.60%) * adjusted_beta (0.94) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.